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Abstract
Background
COPD is a common HIV comorbidity, and HIV-infected individuals have a higher incidence
and earlier onset of COPD compared to HIV-uninfected individuals. While the pathogenesis
of HIV-associated COPD is largely unknown, chronic inflammation may contribute. Four
pneumoproteins known to be markers of lung injury and inflammation have been associated
with COPD in HIV-uninfected individuals: PARC/CCL-18, SP-D, CC-16, and sRAGE.
Objective
To determine whether these pneumoproteins are also associated with pulmonary function
and COPD Assessment Test (CAT) scores in HIV-infected individuals.
Methods
Associations between plasma pneumoprotein levels and pulmonary function were deter-
mined in a cross-sectional study of otherwise healthy HIV-infected individuals enrolled
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Results
Among 65 participants, 78.5% were male, 50.8% had undetectable viral load, and 76.9%
were ever-smokers. Mean post-bronchodilator FEV1/FVC was 0.71, and mean DLco%pre-
dicted was 61%. Higher PARC/CCL-18 was associated with lower DLco%predicted and
higher CAT score. Higher CC-16 was associated with lower DLco%predicted and lower
FVC%predicted.
Conclusions
This exploratory analysis is the first to characterize associations between these four pneu-
moproteins and pulmonary function in an HIV-infected cohort. Our findings suggest the
pathogenesis of HIV-associated COPD may differ from that of non-HIV-associated COPD
due to HIV-specific inflammatory changes affecting DLco. PARC/CCL-18 is associated with
structural and functional pulmonary abnormalities and may be an important COPD bio-
marker candidate in HIV infection. Our study is a preliminary step toward finding clinically
relevant COPD biomarkers in high-risk populations.
Introduction
Chronic obstructive pulmonary disease (COPD) causes significant morbidity and mortality
globally.[1–3] HIV infection may be an independent risk factor for COPD.[4–12] Studies of
HIV-infected persons in the U.S. have reported estimates for COPD prevalence ranging
between 7% and 21%[7,13,14] compared to between 4.2% and 6.4% in the general population.
[15,16] Even when controlling for major COPD risk factors such as smoking status, HIV-
infected individuals tend to develop COPD on average 10 years earlier than HIV-uninfected
individuals.[11,12] Thus, HIV-infected individuals are an important high-risk population in
which to study the pathogenesis of COPD.
Despite substantial epidemiological evidence linking HIV and COPD, the mechanisms
underlying HIV-associated COPD (HIV-COPD) and whether these mechanisms differ from
those in HIV-uninfected persons are not fully understood.[17,18] HIV is known to promote
systemic immune activation and inflammation leading to immunosenescence or immune dys-
regulation that increase the risk of end-organ diseases.[17–23] Proposed mechanisms specific
for HIV-associated COPD include endothelial dysfunction, monocyte activation,[24] and T-
cell activation.[10] Understanding the role of systemic inflammation in HIV-associated COPD
pathogenesis may yield insights about other HIV-associated pulmonary abnormalities includ-
ing reductions in the diffusing capacity for carbon monoxide, DLco, as an isolated decrease in
DLco is the most frequent pulmonary function abnormality observed in HIV-infected popula-
tions.[4,10,20,24]
Spirometry measurements, specifically the ratio of forced expiratory volume in 1 second to
forced vital capacity (FEV1/FVC) measured after bronchodilator administration and FEV1 as a
percentage of the predicted value (FEV1%predicted) are used to diagnose and stage the severity
of COPD, respectively.[25] However, due to the heterogeneity of COPD pathogenesis, the
FEV1/FVC is not always an accurate predictor of progression of COPD and other associated
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clinical outcomes such as symptoms, COPD exacerbations, or mortality.[26,27] Thus, recent
COPD studies have focused on identifying biomarkers that are associated with or predictive of
key clinical endpoints.[28–30]
The most promising COPD biomarker candidates include pneumoproteins associated with
systemic inflammation. Pneumoproteins are produced predominantly in the lung but are pres-
ent in the systemic circulation. Four pneumoproteins of interest for COPD are pulmonary and
activation-regulated chemokine (PARC/CCL-18), surfactant protein-D (SP-D), club cell secre-
tory protein-16 (CC-16), and soluble receptor for advanced glycation end-products (sRAGE).
PARC/CCL-18 and SP-D are pro-inflammatory proteins, and CC-16 and sRAGE are anti-
inflammatory proteins. All of these pneumoproteins are markers of lung injury and inflamma-
tion that have been independently associated with COPD-related outcomes in HIV-uninfected
populations including severity of emphysema (sRAGE),[31] accelerated rate of FEV1 decline
(CC-16),[32,33] increased risk of COPD exacerbations (SP-D),[34] and cardiovascular hospi-
talization and mortality (PARC/CCL-18).[35]
None of these pneumoproteins, however, has been studied for its association with COPD in
HIV-infected individuals. Thus, this cross-sectional analysis of an existing HIV-infected
COPD cohort investigated whether plasma levels of these four pneumoproteins are associated
with pulmonary function and respiratory symptoms. Since HIV is known to increase chronic
systemic inflammation, we hypothesized that HIV may affect the relationship between these
markers of lung inflammation and pulmonary function outcomes.
Methods
Study design, participants, and study protocol
This study is a cross-sectional analysis of the San Francisco arm of the Inflammation, Aging,
Microbes, and Obstructive Lung Diseases (I AM OLD) study, an ongoing study of COPD in
HIV-infected individuals. Participants gave written informed consent, and the study protocol
was approved by the University of California San Francisco Institutional Review Board and the
University of California Berkeley Institutional Review Board. I AM OLD participants are
recruited as inpatients when hospitalized for confirmed pneumonia or as outpatients in the
HIV/AIDS clinic at Zuckerberg San Francisco General Hospital (ZSFG) and followed longitudi-
nally as one of the study aims is examining whether pneumonia is a risk factor for COPD in
HIV. Study visits occurred at ZSFG between September 2016 and June 2017. Inclusion criteria
included HIV-infected status and 18 years of age or older. Exclusion criteria included the pres-
ence of any contra-indications for pulmonary function tests (PFTs), pregnancy, or breastfeeding.
For participants enrolled during a hospitalization for pneumonia, study visits for PFTs
occurred at least 3 months after the end of pneumonia treatment and when they were without
acute or worsening chronic respiratory symptoms. At each visit, participants underwent clini-
cal questionnaires, venous blood draws for pneumoprotein measurements, and PFTs.
Clinical questionnaires
Participants were interviewed by trained staff using a standardized questionnaire. Clinical data
included age, sex, race/ethnicity, history of ever cigarette smoking, cumulative pack-years of ciga-
rette smoking, history of injection drug use (IDU), history of bacterial pneumonia or Pneumocys-
tis jirovecii pneumonia (PCP), and self-reported ART adherence in the past week (yes/no
response to any antiretroviral medication use in the past week). The COPD Assessment Test
(CAT), a validated questionnaire that measures a patient’s self-assessment of the impact of COPD
on their quality of life, was also administered.[36] CD4 count and HIV viral load as well as body
mass index (BMI) were measured at the time of pulmonary function testing.
Pneumoproteins and pulmonary function in HIV
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Blood draws and ELISA assays
Blood was collected in an 8 mL EDTA tube. Specimens were placed on ice and centrifuged
within an hour after collection. Purified plasma aliquots were then stored at -80˚C, shipped to
Case Western Reserve University, and assayed after a single thaw. Levels of pneumoproteins
were measured in purified plasma using commercial ELISA kits (R&D, Minneapolis, Minne-
sota, USA). Replicates were performed in duplicate, and average values were used in analyses.
Pulmonary function tests
Participants were without acute or worsening chronic respiratory symptoms at the time of
PFTs. PFTs consisted of pre- and post-bronchodilator spirometry and measurement of diffus-
ing capacity for carbon monoxide (DLco). We did not measure total lung capacity or residual
volume. Spirometry was performed by trained respiratory technicians, before and after admin-
istering albuterol 360 μg by inhalation from metered dose inhaler. Spirometry and DLco mea-
surements were performed according to American Thoracic Society/European Respiratory
Society (ATS/ERS) guidelines.[37,38] Spirometry reference values were determined from the
third National Health and Nutrition Examination Survey equations and are based on age, sex,
height, and ethnic background.[39] DLco reference values were determined from Crapo et al.
1981 and based on age, sex, and height.[40] The DLco reference values were also adjusted for
hemoglobin and carboxyhemoglobin that were measured at the time of pulmonary function
testing. Spirometry results were overread by a trained respiratory therapist and included only
if they met ATS/ERS criteria for acceptability and reproducibility.
Statistical analysis
Analyses were conducted in Stata version 14.0 (StataCorp; College Station, Texas, USA). Pneu-
moprotein levels were log-transformed and divided by the interquartile range (IQR) to stan-
dardize the dynamic range of the four biomarkers. Using multiple linear regression, we
examined the associations between plasma levels of pneumoproteins and four pulmonary
function outcomes: post-bronchodilator FEV1 as a percentage of the predicted reference value
(FEV1%predicted); post-bronchodilator FVC as a percentage of the predicted reference value
(FVC%predicted); post-bronchodilator FEV1/FVC ratio; and DLco as a percentage of the pre-
dicted value (DLco%predicted) adjusted for hemoglobin and carboxyhemoglobin.
In addition to history of ever cigarette smoking (defined as having smoked at least 100 ciga-
rettes in a lifetime), covariates included age, pack-years of cigarette smoking, BMI, CD4 count,
suppressed or detectable HIV viral load, ART adherence in past week, and history of ever IDU,
bacterial pneumonia, or PCP. Suppressed viral load status was defined as undetectable viral
load<40 copies/mL (Abbott Molecular, Abbott Park, IL, USA). COPD was defined as a post-
bronchodilator FEV1/FVC <0.70,[25] and abnormal DLco%predicted was defined as<80%
and then divided into�60% but<80% (mild impairment) or <60% (moderate to severe
impairment).[41] Age, BMI, and CD4 count were analyzed as continuous variables; all other
predictor variables were dichotomized. Dichotomized independent variables included post-
bronchodilator FEV1/FVC ratio (<0.70 or�0.70) and DLco%predicted (<60% or�60%).
Continuous independent variables included FEV1%predicted, FVC%predicted, and CAT
score. Age and sex were not included as predictor variables in multivariate analyses for FEV1%
predicted, FVC%predicted, or DLco%predicted because the reference equations adjust for age
and sex.
Spearman rank-order correlation coefficient was used to test initial unadjusted associations
between plasma biomarkers and pulmonary function outcomes. Backward elimination was
performed to determine which covariates to include in multivariable analysis for each
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pulmonary function outcome with pneumoprotein measurements omitted. Covariates with a
significance of at least P = 0.05 were retained in multivariable models. Regardless of signifi-
cance, history of ever cigarette smoking was included in each multivariable model because cig-
arette smoking is strongly associated with obstructive lung disease.[42] Once covariates were
determined, separate multivariable models for each pneumoprotein were run for each pulmo-
nary function outcome.
The two-sample t-test was used to determine whether clinical, pneumoprotein, and pulmo-
nary function measurements differed by ART use (ART use in past week versus no ART use in
past week), CD4 count (<200 cells/μL versus CD4 count�200 cells/μL), or HIV viral load
(suppressed versus detectable) indicating extent of immune dysregulation. Pearson correlation
coefficients for pairs of the different biomarkers were also calculated.
Results
Baseline characteristics
Overall, 65 participants were enrolled; 78.5% were male, and the median age was 51 years
(Table 1). Of the participants, 76.9% were ever-smokers for whom the median pack-years of
smoking was 23 years and 39.7% reported ever IDU (n = 63). Over 92% reported adherence to
their ART regimen in the past week; 50.8% had an undetectable viral load, and another 29.2%
had a detectable HIV viral load that was <40 copies/mL. The median CD4 cell count was 455
cells/μL, and 26.2% had a CD4 cell count <200 cells/μL. The majority (75.4%) had a history of
bacterial pneumonia, and 38.5% had a history of PCP.
Associations between pneumoproteins and lung function or CAT score
Using Spearman correlations, significant associations were found between PARC/CCL-18 and
DLco%predicted (R = -0.33, P = 0.0072) or CAT (R = 0.56, P<0.0001) and between sRAGE
and DLco%predicted (R = -0.26, P = 0.037) (Table 2).
Spirometry. No statistically significant associations were found between any pneumopro-
tein and post-bronchodilator FEV1/FVC ratio in analyses adjusted for age, history of ever
smoking, and BMI (Table 3). However, higher levels of CC-16 were independently associated
with lower FVC%predicted (n = 60; β = -6.6, P = 0.012) adjusted for history of ever smoking
and BMI. There was also a trend toward statistical significance between higher PARC/CCL-18
levels and lower FVC%predicted (β = -4.4, P = 0.10). Similarly, after adjusting for history of
ever smoking, there were trends toward statistical significance between higher CC-16 levels
and lower FEV1%predicted (n = 60; β = -5.8, P = 0.07) and higher PARC/CCL-18 levels and
lower FEV1%predicted (β = -5.4, P = 0.10).
Diffusing capacity. Several pneumoproteins were independently associated with DLco%
predicted adjusted for a history of ever smoking and BMI (Table 3). Higher PARC/CCL-18 (β
= -8.3, P< 0.001), higher CC-16 (n = 60; β = -4.5, P = 0.044), and higher sRAGE (β = -4.2,
P = 0.038) levels were all independently associated with lower DLco%predicted, adjusted for
these covariates.
When a history of ever smoking was substituted with pack-years of smoking, the associa-
tions between PARC/CCL-18 and DLco%predicted (n = 64; β = -6.5, P = 0.004) and between
CC-16 and DLco%predicted (n = 59; β = -4.7, P = 0.029) adjusted also for ART adherence in
the past week remained statistically significant (Table 3). However, the adjusted association
between sRAGE and DLco%predicted was no longer significant (n = 64; β = -1.8, P = 0.39).
Since reductions in diffusing capacity are non-specific and may be related to conditions
including pulmonary vascular disease that develops as a result of injection drug use (39.7%
reported ever injection drug use, n = 63), we performed additional analyses adjusting for IDU.
Pneumoproteins and pulmonary function in HIV
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Table 1. Baseline clinical characteristics, pulmonary function tests, and pneumoprotein levels.
Baseline characteristics (n = 65 unless noted)
Characteristic Value
Male sex (assigned at birth) (%) 51 (78.5%)
Median age (years) (IQR) 51 years (45–59 years)
Race/ethnicity1
- White (%) 25 (38.5%)
- Black (%) 27 (41.5%)
- Hispanic (%) 10 (15.4%)
- Native Hawaiian or Other Pacific Islander (%) 6 (9.2%)
- American Indian/Alaska Native 7 (10.8%)
- Mixed (%) 5 (7.7%)
- Other (%) 6 (9.2%)
BMI, median (IQR) 26.5 (7.14)
Ever-cigarette smokers (%) 50 (76.9%)
- Median pack-years smoking, n = 46 (IQR) 23 years (10–44 years)
Ever injection drug use (%), n = 63 25 (39.7%)
Current ART use in the past week (%) 60 (92.3%)
Median CD4 count (cells/μL) (IQR) 455 cells/μL (189–651 cells/μL)
- Number of participants with CD4 count < 200 cells/μL 17 (26.2%)
Undetectable viral load (%) 33 (50.8%)
- Participants with detectable viral load < 40 copies/mL 19 (29.2%)
- Participants with detectable viral load� 40 copies/mL 13 (20%)
Past history of bacterial pneumonia ever (%) 49 (75.4%)
- Past history of bacterial pneumonia in last 6 months (% out of 49 participants with past history of bacterial pneumonia) 12 (24.5%)
Past history of Pneumocystis jirovecii pneumonia (%) 25 (38.5%)
Pulmonary function tests and CAT score Value
Mean post-BD FEV1%predicted (standard error) 83% (2.7%)
Mean post-BD FVC%predicted (standard error) 92% (2.2%)
Mean post-BD FEV1/FVC ratio (standard error) 0.71 (0.02)
- Number of participants with post-BD FEV1/FVC <0.70 23 (35.4%)
Mean DLco%predicted (standard error) 61% (1.8%)
- Number of participants with DLco%predicted <80% 59 (90.8%)
- Number of participants with DLco%predicted <60% 31 (47.7%)
Median CAT score, n = 60 (IQR) 13.5 (4.5–20.5)
Pneumoprotein level Value
Median CC-16 level (IQR) for n = 60 33.9 ng/mL (21.5–46.7 ng/mL)
Median PARC/CCL-18 level (IQR) 55.0 ng/mL (38.8–86.8 ng/mL)
Median sRAGE level (IQR) 0.033 ng/mL (0.017–0.049 ng/mL)
Median SP-D level (IQR) 33 ng/mL (17–49 ng/mL)
1Race/ethnicity percentages do not add up to 100 because multiple choices were possible.
Abbreviations: ART = antiretroviral therapy; post-BD = post-bronchodilator; BMI = body mass index; CAT = COPD Assessment Test; CC-16 = club cell secretory
protein-16; DLco%predicted = diffusing capacity for carbon monoxide corrected as percentage of predicted reference value; FEV1%predicted = forced expiratory
volume in 1 second as percentage of predicted reference value; FEV1/FVC ratio = ratio of forced expiratory volume in 1 second to forced vital capacity; FVC%
predicted = forced vital capacity as percentage of predicted reference value; IQR = interquartile range; PARC/CCL-18 = pulmonary and activation-regulated chemokine;
SP-D = surfactant protein-D; sRAGE = soluble receptor for advanced glycation end-products.
The mean post-bronchodilator FEV1/FVC ratio was within normal limits but was relatively low (0.71), and 35.4% of participants had COPD (FEV1/FVC <0.70). The
mean post-bronchodilator FEV1%predicted was 83%, and the mean post-bronchodilator FVC%predicted was 92%. In contrast, the mean percent-predicted DLco (DLco
%predicted) was abnormal (61%), and most participants had impaired diffusing capacity: 90.8% had mildly reduced DLco%predicted (<80%), and 47.7% had
moderately to severely reduced DLco%predicted (<60%). In addition, the median CAT score was 13.5 (n = 60), indicating a “medium” impact of COPD on a
participant’s life.
https://doi.org/10.1371/journal.pone.0223263.t001
Pneumoproteins and pulmonary function in HIV
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When past history of IDU was forced into the multivariable models, PARC/CCL-18 (n = 63; β
= -8.6, P< 0.001) and CC-16 (n = 59; β = -4.5, P = 0.045) were still significantly associated
with DLco%predicted, and the association between sRAGE and DLco%predicted approached
statistical significance (n = 63; β = -4.5, P = 0.053) adjusted also for history of ever smoking
and BMI (Table 3).
CAT score. Only higher PARC/CCL-18 was independently associated with higher total
CAT score (n = 60; β = 6.7, P< 0.001) adjusted for ever history of bacterial pneumonia
(Table 3).
Table 2. Unadjusted associations between plasma pneumoprotein levels and pulmonary function testing out-
comes using Spearman’s correlation (unless otherwise noted, n = 65).
Spearman’s ρ P value
Post-BD FEV1%predicted
CC-16 (n = 60) -0.16 0.22
PARC/CCL-18 -0.064 0.61
sRAGE -0.059 0.64
SP-D -0.061 0.63
Post-BD FVC%predicted
CC-16 (n = 60) -0.25 0.055§
PARC/CCL-18 -0.16 0.20
sRAGE -0.066 0.60
SP-D -0.10 0.41
Post-BD FEV1/FVC
CC-16 (n = 60) -0.030 0.82
PARC/CCL-18 -0.0012 0.99
sRAGE 0.047 0.71
SP-D -0.042 0.74
DLco%predicted
CC-16 (n = 60) -0.17 0.18
PARC/CCL-18 -0.33 0.0072�
sRAGE -0.26 0.037�
SP-D 0.018 0.89
CAT
CC-16 (n = 60) 0.099 0.45
PARC/CCL-18 (n = 60) 0.56 <0.0001�
sRAGE (n = 60) 0.045 0.73
SP-D (n = 60) -0.037 0.78
Note that all pneumoproteins measurements were log-transformed and divided by interquartile range. All
spirometry measurements are post-bronchodilator values.
� P < 0.05
§ P� 0.10
Abbreviations: post-BD = post-bronchodilator; BMI = body mass index; CAT = COPD Assessment Test; CC-
16 = club cell secretory protein-16; DLco%predicted = diffusing capacity for carbon monoxide corrected as
percentage of predicted reference value; FEV1%predicted = forced expiratory volume in 1 second as percentage of
predicted reference value; FEV1/FVC ratio = ratio of forced expiratory volume in 1 second to forced vital capacity;
FVC%predicted = forced vital capacity as percentage of predicted reference value; PARC/CCL-18 = pulmonary and
activation-regulated chemokine; SP-D = surfactant protein-D; sRAGE = soluble receptor for advanced glycation end-
products.
https://doi.org/10.1371/journal.pone.0223263.t002
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Table 3. Adjusted associations between plasma pneumoprotein levels and pulmonary function testing outcomes (unless otherwise noted, n = 65).
β❖ P value Lower 95% confidence interval Upper 95% confidence interval
Post-BD FEV1%predicteda
CC-16 (n = 60) -5.8 0.07§ -12 0.49
PARC/CCL-18 -5.4 0.10§ -12 1.1
sRAGE -2.2 0.46 -8.2 3.7
SP-D -1.3 0.67 -7.3 4.7
Post-BD FVC%predictedb
CC-16 (n = 60) -6.6 0.012� -12 -1.5
PARC/CCL-18 -4.4 0.10§ -9.8 0.91
sRAGE -1.3 0.58 -6.2 3.5
SP-D -1.2 0.63 -6.1 3.7
Post-BD FEV1/FVCc
CC-16
(n = 60)
-0.0016 0.94 -0.043 0.040
PARC/CCL-18 -0.0017 0.94 -0.047 0.043
sRAGE 0.011 0.63 -0.033 0.055
SP-D 0.0013 0.95 -0.038 0.041
DLco%predictedb
CC-16 (n = 60) -4.5 0.044� -8.8 -0.12
PARC/CCL-18 -8.3 <0.001� -12 -4.2
sRAGE -4.2 0.038� -8.2 -0.24
SP-D 0.25 0.91 -3.9 4.4
DLco%predictedd
CC-16 (n = 59) -4.7 0.029� -8.8 -0.49
PARC/CCL-18 (n = 64) -6.5 0.004� -11 -2.2
sRAGE (n = 64) -1.8 0.39 -6.0 2.4
SP-D (n = 64) 0.82 0.69 -3.2 4.8
DLco%predictede
CC-16 (n = 59) -4.5 0.045� -9.0 -0.11
PARC/CCL-18 (n = 63) -8.6 <0.001� -13 -4.3
sRAGE (n = 63) -4.5 0.053§ -9.1 0.053
SP-D (n = 63) 0.23 0.92 -4.1 4.5
CATf
CC-16 (n = 60) 1.6 0.27 -1.3 4.5
PARC/CCL-18 (n = 60) 6.7 <0.001� 3.9 9.5
sRAGE (n = 60) -0.22 0.88 -3.1 2.6
SP-D (n = 60) -1.4 0.32 -4.2 1.4
Note that all pneumoproteins measurements were log-transformed and divided by interquartile range. All spirometry measurements are post-bronchodilator values.
Variables with P < 0.20 in unadjusted analyses were included in multivariate analyses and retained to maximize adjusted R-squared. Regardless of significance of
association, ever smoker variable was included in each multivariate model.
a Adjusted for history of ever cigarette smoking
b Adjusted for history of ever cigarette smoking and BMI
c Adjusted for history of ever cigarette smoking, age, and BMI
d Adjusted for pack-years of cigarette smoking and ART adherence in past week
e Adjusted for history of ever cigarette smoking, BMI, and history of ever injection drug use
f Adjusted for history of ever bacterial pneumonia
� P < 0.05
§ P� 0.10
❖ Per IQR increase in log10 values
Abbreviations: post-BD = post-bronchodilator; BMI = body mass index; CAT = COPD Assessment Test; CC-16 = club cell secretory protein-16; DLco%
predicted = diffusing capacity for carbon monoxide corrected as percentage of predicted reference value; FEV1%predicted = forced expiratory volume in 1 second as
percentage of predicted reference value; FEV1/FVC ratio = ratio of forced expiratory volume in 1 second to forced vital capacity; FVC%predicted = forced vital capacity
as percentage of predicted reference value; PARC/CCL-18 = pulmonary and activation-regulated chemokine; SP-D = surfactant protein-D; sRAGE = soluble receptor
for advanced glycation end-products.
https://doi.org/10.1371/journal.pone.0223263.t003
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Pneumoprotein levels and pulmonary function stratified by HIV viral
suppression status, CD4 cell count, or ART use in last week
To assess whether severity of immune dysfunction in HIV infection affects pneumoprotein
levels or pulmonary function levels, the data were stratified by each HIV-associated covariate:
HIV viral load, CD4 cell count, or ART status. Clinical, pneumoprotein, and pulmonary func-
tion measurements did not differ significantly by these covariates except for expected associa-
tions—i.e., participants not on ART in the past week had higher viral loads (P = 0.0064) and a
trend toward lower CD4 cell counts (P = 0.09).
Correlations between biomarkers
As combinations of biomarkers have been found to be more highly correlated with inflamma-
tion or COPD clinical outcomes than single biomarkers,[43,44] correlations between biomark-
ers were analyzed. CC-16 was moderately correlated with PARC/CCL-18 (R = 0.32, P = 0.012),
and no other correlation between biomarkers was observed.
Discussion
In this cross-sectional exploratory analysis, we assessed the associations between plasma levels
of four pneumoproteins and pulmonary function outcomes or CAT score. To our knowledge,
this is the first study to characterize these associations specifically in an HIV-infected cohort.
We found that higher PARC/CCL-18 levels and higher CC-16 levels were significantly associ-
ated with lower DLco%predicted. In one analysis, higher sRAGE levels were significantly asso-
ciated with lower DLco%predicted. In addition, higher CC-16 levels were significantly
associated with lower FVC%predicted, and higher PARC/CCL-18 levels were significantly
associated with higher CAT score.
Our results support prior findings that an impaired diffusing capacity is one of the most
common HIV-associated pulmonary function abnormalities.[4,9,14,45] In these studies, a
moderately to severely reduced DLco was reported in 29% to 36.5% of HIV-infected partici-
pants. In our cohort, nearly 48% had a DLco%predicted <60%, a cut-off indicative of moder-
ate (or worse) impairment in diffusing capacity. This high proportion likely is due to our
recruitment strategy to enroll HIV-infected participants with acute pneumonia (but perform
PFTs only after recovery from pneumonia) as a past history of bacterial pneumonia or PCP
have both been associated with permanent reductions in DLco in a large multicenter study.44
Our results also underscore the need to understand mechanisms underlying reductions in dif-
fusing capacity as a DLco%predicted <60% has been associated with an increased mortality in
a recent multicenter study.[45]
We found that higher PARC/CCL-18 levels were significantly associated with lower DLco%
predicted. While the biological role of PARC/CCL-18 is not fully understood, it is secreted pri-
marily by innate immune cells like monocytes/macrophages and dendritic cells and is chemotac-
tic for T-cells.[46,47] PARC/CCL-18 increases fibrosis in vivo,[48] and serum levels are elevated
in idiopathic pulmonary fibrosis.[49] Higher serum PARC/CCL-18 levels have been associated
not only with COPD[35] but also with increased risk for hospitalized COPD exacerbations[50]
and lower DLco, higher COPD exacerbation rate, and higher BODE index (a clinical index incor-
porating BMI, level of airflow obstruction, dyspnea, and 6 minute walk distance)[51] in a panel
with other proteins in subjects with COPD versus subjects without COPD.[44] As HIV is known
to enter airway epithelial cells and increase release of inflammatory mediators,[52] our findings
suggest that increased PARC/CCL-18 levels could reflect local pulmonary inflammation leading
to destruction of alveolar walls and irreversible enlargement of airspaces in emphysema.
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While previous studies have shown that lower CC-16 levels are associated with COPD and
decreased lung function,[33,53,54] we found that higher CC-16 levels were significantly associated
with lower DLco%predicted. This may indicate that the pathogenesis of HIV-associated COPD
may differ from that of COPD in those without HIV due to HIV-specific inflammatory changes
that impair diffusing capacity. Similar to how HIV increases chronic systemic inflammation and
causes increased gut epithelial permeability and microbial translocation into the blood,[55,56]
HIV might also damage the alveolar-capillary barrier, allowing more CC-16 to move into the
peripheral blood. Another possible explanation is that the negative association between CC-16
and DLco may suggest the presence of interstitial lung disease as the etiology underlying the dif-
fusing capacity abnormality. While past studies have shown an association between lower CC-16
levels and COPD, other studies have shown an association between (transient) increases in CC-16
and acute lung injuries like fire or cigarette smoke,[53,57] ozone,[58] and even certain interstitial
lung diseases, idiopathic pulmonary fibrosis, and systemic sclerosis-associated interstitial lung dis-
ease.[54,59,60] CC-16 is thought to help reduce airway inflammation[61] and protect the respira-
tory tract from oxidative stress.[62] Larger longitudinal studies will be required to understand
how CC-16 may be associated with DLco%predicted and COPD in HIV-infected populations.
Previous studies have shown that lower sRAGE levels are associated with COPD.[31,63,64]
However, we found that higher sRAGE levels were associated with lower DLco%predicted in a
single analysis. sRAGE is a decoy receptor of RAGE that detects stresses like hypoxia and oxi-
dative stress and binds ligands associated with damage-associated molecular patterns to pro-
tect against inflammation.[31,63] Increasing evidence suggests that lower sRAGE levels may
play a mechanistic role in worse lung function outcomes including COPD status as well as
reduced DLco[31] and greater emphysema severity;[64] thus, lower sRAGE levels may reflect
damage to airways or lung parenchyma respectively. Our findings may be attributed to differ-
ent explanations similar to those for CC-16: HIV-specific inflammatory changes may impair
diffusing capacity but also damage the alveolar-capillary barrier and allow more sRAGE to
move into the peripheral blood.
Our finding that none of the pneumoproteins was significantly associated with post-bron-
chodilator FEV1/FVC as hypothesized may not be entirely surprising. COPD is a heteroge-
neous and complex disease with variable clinical presentations driven by different underlying
pathogenic mechanisms.[65,66]
While these pneumoproteins have been studied in HIV-uninfected individuals, they may
not reflect the specific inflammatory mediators that contribute to COPD in HIV-infected indi-
viduals. We found that DLco and spirometry measurements did not differ significantly by
viral load, CD4 cell count, or ART use. Pneumoproteins associated with changes in the lung
microbiome[67] or cellular senescence of T lymphocytes[9,68] could be further explored as
potential biomarkers for progression or development of HIV-associated COPD.
Besides structural abnormalities like impaired DLco or decreased FEV1/FVC, functional
abnormalities are common in HIV-infected individuals.[69] COPD may have highly variable
clinical manifestations among different patients;[70] thus, other measurements like self-assess-
ment of health status have become increasingly important. The CAT is a 40-point question-
naire that asks patients to self-report how COPD affects their health status.[36] While there is
no “target” total CAT score, a change in 2 or more points may represent a clinically significant
change in health status[71] and can help inform clinical management of COPD.[72] The asso-
ciation between higher PARC/CCL-18 levels and lower DLco%predicted or higher total CAT
score suggests that PARC/CCL-18 may be associated with not only structural but also func-
tional impairments in COPD, which may be an important consideration for a COPD bio-
marker candidate. Alternatively, HIV-infected individuals may be at higher risk for
emphysema compared to other COPD subtypes.
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Important limitations of our study include its cross-sectional design: without longitudinal
follow-up, we could not examine causality and related COPD outcomes such as rate of FEV1
decline, COPD exacerbations, hospitalizations and mortality. While previous cohort studies
did show that these pneumoproteins were associated with COPD or related outcomes during
follow-up, the changes in these pneumoproteins could be due to other mechanisms besides
HIV infection driving pulmonary function impairment. Also, with a relatively small sample
size, the study lacked power to detect effect sizes previously reported.[33–35] Furthermore, we
were unable to account for other diseases (i.e., inflammatory co-morbidities) or immunomod-
ulatory medications that may have affected plasma pneumoprotein levels and concurrent
restrictive lung disease that may have affected FVC%predicted. Future studies could examine
these factors and whether these pneumoproteins are not only associated with but also causally
linked with structural and functional pulmonary abnormalities in HIV-infected individuals;
this would help elucidate whether statistically significant differences in these pneumoproteins
lead to clinically meaningfully differences in COPD outcomes.
Our study also had several strengths. First, this is a well-characterized cohort with paired
blood-pulmonary function data. Although an exploratory analysis, our study includes the
major HIV-associated and COPD-associated clinical or demographic covariates identified as
important predictors. Second, this is also the first study to characterize associations between
pneumoproteins, specifically those that are markers for lung inflammation and injury associ-
ated with COPD, with pulmonary function measurements in an HIV-infected cohort. Our
study is a preliminary step toward finding early biomarkers of adverse respiratory outcomes
that could help prevent and manage COPD in high-risk populations. Finally, further insights
about HIV-associated COPD may help improve understanding of both COPD and other HIV-
associated comorbidities.
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